BAUSCH Health

2017

Register for email alerts.

All Categories

Archive

Date 12/29/17

Title

Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

Download PDF

Date 12/22/17

Title

Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness

Download PDF

Date 12/20/17

Title

Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

Download PDF

Date 12/18/17

Title

Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

Download PDF

Date 12/15/17

Title

Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

Download PDF

Date 12/07/17

Title

Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Download PDF

Date 12/04/17

Title

Valeant Announces Pricing Of Private Offering Of Senior Notes

Download PDF

Date 12/04/17

Title

Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount

Download PDF

Date 12/04/17

Title

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount

Download PDF

Date 12/04/17

Title

Valeant Announces Launch Of Private Offering Of Senior Notes

Download PDF

Date 11/21/17

Title

Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

Download PDF

Date 11/21/17

Title

Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Download PDF

Date 11/15/17

Title

Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program

Download PDF

Date 11/14/17

Title

Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes

Download PDF

Date 11/14/17

Title

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

Download PDF

Date 11/13/17

Title

Valeant Announces Launch of Private Offering of Add-On Secured Notes

Download PDF

Date 11/10/17

Title

Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.

Download PDF

Date 11/08/17

Title

Valeant To Participate At The Stifel 2017 Healthcare Conference

Download PDF

Date 11/07/17

Title

Valeant Announces Third-Quarter 2017 Results

Download PDF

Date 11/06/17

Title

Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

Download PDF

Date 11/02/17

Title

Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

Download PDF

Date 11/02/17

Title

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

Download PDF

Date 10/31/17

Title

Valeant Will Reduce Debt By Additional $125 Million

Download PDF

Date 10/16/17

Title

Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

Download PDF

Date 10/12/17

Title

Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile

Download PDF

Date 10/04/17

Title

Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology

Download PDF

Date 10/03/17

Title

Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe

Download PDF

Date 10/03/17

Title

Valeant Will Release Third-Quarter 2017 Financial Results On November 7

Download PDF

Date 10/02/17

Title

Valeant Announces Pricing Of Private Offering Of Senior Secured Notes

Download PDF

Date 10/02/17

Title

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount

Download PDF

Date 10/02/17

Title

Valeant Announces Launch Of Private Offering Of Senior Secured Notes

Download PDF

Date 09/29/17

Title

Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group

Download PDF

Date 09/27/17

Title

Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans

Download PDF

Date 09/27/17

Title

Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference

Download PDF

Date 09/18/17

Title

Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference

Download PDF

Date 09/18/17

Title

Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference

Download PDF

Date 09/15/17

Title

Valeant Commits $200,000 to Support Hurricane Relief Efforts

Download PDF

Date 09/06/17

Title

Valeant To Participate At The Morgan Stanley Global Healthcare Conference

Download PDF

Date 09/05/17

Title

Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

Download PDF

Date 08/16/17

Title

Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility

Download PDF

Date 08/09/17

Title

Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy

Download PDF

Date 08/08/17

Title

Valeant Announces Second-Quarter 2017 Results

Download PDF

Date 08/07/17

Title

Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA

Download PDF

Date 07/27/17

Title

Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

Download PDF

Date 07/17/17

Title

Valeant Agrees To Sell Obagi Medical Products Business

Download PDF

Date 07/13/17

Title

Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018

Download PDF

Date 07/10/17

Title

Valeant Announces Q2 2017 Financial Results Date And Conference Call Details

Download PDF

Date 07/10/17

Title

Valeant Pays Down $811 Million of Senior Secured Term Loans

Download PDF

Date 07/06/17

Title

Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses

Download PDF

Date 06/29/17

Title

Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group

Download PDF

Date 06/28/17

Title

Salix Announces Filing Acceptance For Plenvu®* Next Generation Bowel Cleansing Preparation For Colonoscopies

Download PDF

Date 06/22/17

Title

Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International

Download PDF

Date 06/19/17

Title

Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications

Download PDF

Date 06/19/17

Title

John Paulson Joins Valeant Board Of Directors

Download PDF

Date 06/08/17

Title

Valeant Announces Sale of iNova Pharmaceuticals for $930 Million

Download PDF

Date 05/31/17

Title

Valeant Pharmaceuticals To Present At Financial Industry Conferences

Download PDF

Date 05/22/17

Title

Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution

Download PDF

Date 05/17/17

Title

Statement Regarding Xifaxan Intellectual Property Litigation

Download PDF

Date 05/10/17

Title

Valeant Pharmaceuticals To Present At Health Care Conferences

Download PDF

Date 05/09/17

Title

Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

Download PDF

Date 05/08/17

Title

Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%

Download PDF

Date 05/05/17

Title

Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership

Download PDF

Date 05/03/17

Title

Valeant Announces 2017 Annual Meeting Results

Download PDF

Date 05/01/17

Title

Valeant Announces Additional Debt Reduction Of Approximately $220 Million

Download PDF

Date 04/26/17

Title

Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System

Download PDF

Date 04/21/17

Title

Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis

Download PDF

Date 04/10/17

Title

Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call

Download PDF

Date 04/06/17

Title

Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform

Download PDF

Date 03/30/17

Title

Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced

Download PDF

Date 03/21/17

Title

Valeant Completes Refinancing Transactions

Download PDF

Date 03/20/17

Title

Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018

Download PDF

Date 03/20/17

Title

Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

Download PDF

Date 03/15/17

Title

Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses

Download PDF

Date 03/10/17

Title

Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement

Download PDF

Date 03/10/17

Title

Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018

Download PDF

Date 03/10/17

Title

Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes

Download PDF

Date 03/09/17

Title

Valeant Announces Launch Of Private Offering Of Senior Secured Notes

Download PDF

Date 03/07/17

Title

Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018

Download PDF

Date 03/06/17

Title

Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement

Download PDF

Date 03/03/17

Title

Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal

Download PDF

Date 03/01/17

Title

Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation

Download PDF

Date 02/28/17

Title

Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance

Download PDF

Date 02/27/17

Title

Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity

Download PDF

Date 02/27/17

Title

Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod

Download PDF

Date 02/23/17

Title

Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products

Download PDF

Date 02/21/17

Title

Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients

Download PDF

Date 02/16/17

Title

Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis

Download PDF

Date 02/13/17

Title

Valeant Pharmaceuticals To Participate At Healthcare Conferences

Download PDF

Date 01/30/17

Title

Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance

Download PDF

Date 01/10/17

Title

Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses

Download PDF

Date 01/10/17

Title

Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118

Download PDF

Date 01/10/17

Title

Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion

Download PDF

Date 01/09/17

Title

Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash

Download PDF

Date 01/04/17

Title

Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Download PDF

Date 01/04/17

Title

Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors

Download PDF

Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

848-264-0934

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE